A Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract

Official Title

A Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract

Summary:

This multicentre study will assess the safety of atezolizumab as second-line treatment for participants with locally advanced or metastatic urothelial or non-urothelial cancer of the urinary tract in addition to evaluate the efficacy of atezolizumab and potential tumour biomarkers associated with atezolizumab.

Trial Description

Primary Outcome:

  • Percentage of Participants With Adverse event
Secondary Outcome:
  • Overall Survival (OS)
  • Progression Free Survival (PFS) as per Response Evaluation Criteria in Solid Tumours Version 1.1 (RECIST v1.1)
  • Percentage of Participants With Best Overall Response as Assessed by RECIST v1.1
  • Percentage of Participants With Disease Control as Assessed by RECIST v1.1
  • Duration of Response as Assessed by RECIST v1.1
  • Change From Baseline in Health-Related Quality of Life (HRQoL), as Assessed Using European Organization for Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire Core 30 (QLQ-C30) Score
  • Change from Baseline in EuroQoL (European Quality of Life) Group 5-Dimension 5-Level Self Report Questionnaire (EQ-5D-5L) Health Utility Score

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society